# Safety Study of a Fluorescent Marker to Visualize Cancer Cells

Source: https://onco.cc/trials/nct02097875/  
OnCo record `nct02097875` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Tozuleristide run by Blaze Bioscience Australia Pty Ltd, completed.

## Summary

Safety Study of a Fluorescent Marker to Visualize Cancer Cells is a phase 1 interventional study registered as NCT02097875 by Blaze Bioscience Australia Pty Ltd, with 21 participants enrolled, started 2013-12. Conditions recorded: Skin Neoplasms. Interventions recorded: BLZ-100.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02097875
- Phase: 1
- Setting: A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Skin Cancer
- Sponsor: Blaze Bioscience Australia Pty Ltd
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT02097875: https://clinicaltrials.gov/study/NCT02097875

## Connected records

- cancers: [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- drugs: [Tozuleristide](https://onco.cc/drugs/blz-100/)
- companies: [Blaze Bioscience](https://onco.cc/companies/blaze-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct02097875.json